http://articles.mercola.com/sites/articles/archive/2008/11/22/proof-that-fibromyalgia-is-real.aspx
georgeeby [ Joined on 03/08 ] [ Posted on November 22, 2008
Fibromyalgia is a man-made disease and is a side effect common to an entire class of drugs, the quinolones and flouroquinolones. Do your homework.
http://en.wikipedia.org/wiki/Quinolone
The quinolones are a family of synthetic broad-spectrum antibiotics. The parent of the group is nalidixic acid....Quinolones and fluoroquinolones are bactericidal drugs, actively killing bacteria.
Side-effects from fluoroquinolones can be mild and
short-lived or they can be severe and long-lasting after therapy has
been discontinued. If side-effects affecting the
central nervous system,
peripheral nervous system, or
muscular
system occur, the patient should discontinue therapy and consult
with his/her doctor. The side-effects from fluoroquinolones include
tingling,
anxiety,
numbness,
twitching,
joint pain,
muscle pain,
tendinitis,
fear,
blurred vision,
memory loss,
diarrhea, severe
panic attacks,
insomnia, tear
of achilles
tendon,
confusion, impaired concentration, burning pain,
carpal
tunnel syndrome,
nightmares,
confusion,
tachycardia,
nausea,
palpitations,
hyperesthesia,
fatigue,
depersonalisation,
pins and
needles sensation,
muscular
spasms, tremors,
headaches,
agitation,
hallucinations,
psychosis,
tinnitus,
skin rash,
hair loss,
abdominal
pain,
visual
disturbances.[2]
Peripheral neuropathy (nerve damage): "Rare cases of sensory or sensor motor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoaesthesias, dysesthesias, and weakness have been reported in patients taking quinolones. Therapy should be discontinued if the patient experiences symptoms of neuropathy, including pain, burning, tingling, numbness and/or weakness, or is found to have deficits in light touch, pain, temperature, position sense, vibratory sensation, and/or motor strength, in order to prevent the development of an irreversible condition."[3]
Tendon damage: "Ruptures of the shoulder, hand, Achilles tendon, or other tendons that require surgical repair or resulted in prolonged disability have been reported in patients receiving quinolones. Post-marketing surveillance reports indicate that this risk may be increased in patients receiving concomitant corticosteroids, especially the elderly. Fluoroquinolone therapy should be discontinued if the patient experiences pain, inflammation, or rupture of a tendon. Patients should rest and refrain from exercise until diagnosis of tendinitis or tendon rupture had been excluded. Tendon rupture can occur during or after therapy with quinolones." On July 8, 2008, the FDA requested manufacturers to include a black box warning for tendon damage.[4]
Kidney stones due to loss of Oxalobacter formigenes[5]
http://www.medfamily.org/dictionary/F/terms-FLOUROQUINOLONES.phtml
FLOUROQUINOLONES
A family of antibiotics, including Ciprofloxacin, ofloxacin, and Sparfloxacin. Sometimes used as components of combination therapy for mycobacterium avium complex.
Side effects
The fluoroquinolones as a class are generally well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they can have serious adverse effects.
Fluoroquinolones are approved for use only in people older than 18. They can affect the growth of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy is not recommended unless the benefits justify the potential risks to the fetus. These agents are also excreted in breast milk and should be avoided during breast-feeding if at all possible.
Gastrointestinal effects. The most common adverse events experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms such as dizziness occurred in about 50% of the patients.
Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight should be avoided during treatment and several days (5 days with sparfloxacin) after the use of the drug. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids.
Hepatoxicity. Trovafloxacin use has been associated with rare liver damage, which prompted the withdrawal of the oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious that the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones have been found to produce additional toxicities to the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild.
Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and are generally mild to moderate in severity, and usually resolve after treatment is stopped.